Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 9, 2000, Pages 3077-3084

  Cusi, Kenneth ^a,b   DeFronzo, Ralph ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; RECOMBINANT SOMATOMEDIN C;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER METABOLISM; MALE; METABOLIC REGULATION; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0033694512     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.9.3077     Document Type: Article

References (61)

1. Insulin-like growth factor I: Physiology, metabolic effects and clinical uses
2. Insulin-like growth factor binding proteins and their role in controlling IGF actions
3. Treatment of NIDDM, IDDM and other insulin resistant states with IGF-I
4. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome
5. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes
6. High dose intravenous, but not low dose subcutaneous, insulin-like growth factor-I therapy induces sustained insulin sensitivity in severely resistant type I diabetes mellitus
7. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance
8. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus
9. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM
10. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus
11. Short-term effects of recombinant human insulin-like growth factor I on metabolic control in patients with type II diabetes mellitus
12. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus
13. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes
14. Evidence from a dose-ranging study that recombinant insulin-like growth factor I (rhIGF-I) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus
15. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients
16. Safety profiling of rhIGF-I therapy in patients with NIDDM: A dose-ranging, placebo controlled trial
17. Insulin-like growth factor I therapy for diabetes mellitus?
18. Effect of inscreasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man
19. Effects of recombinant human IGF-I on glucose and leucine kinetics in men
20. Comparison of the effects of rhIGF-I and insulin on glucose and leucine kinetics in man
21. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study
22. The hot but not the cold minimal model allows precise assessment of insulin sensitivity in NIDDM subjects
23. Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism
24. Comparison of metabolic effects of recombinant human insulin-like growth factor-I and insulin
25. rhIGF-I administration in humans: Differential metabolic effects of bolus vs. continuous subcutaneous delivery
26. Impaired insulin growth factor I-mediated stimulation of glucose incorporation into glycogen in vivo in the ob/ob mouse
27. Simultaneous insulin-like growth factor I and insulin resistance in obese Zucker rats
28. Glucose clamp technique: A method for quantifying insulin secretion and resistance
29. Indirect calorimetry: Methodological and interpretative problems
30. Serum concentrations of insulin-like growth factor II are not changed by short term fasting and refeeding
31. Determination of blood sugar
32. Contributions by kidney and liver to glucose production in the postabsorptive state and after 60h of fasting
33. Measurement of size and turnover rate of body glucose pool by the isotope dilution method
34. 14C glucose
35. Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method
36. 13C nuclear magnetic resonance spectroscopy
37. A review of body composition studies with emphasis on total body water and fat
38. Lilly Lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM
39. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus; contributions of excessive hepatic glucose production and impaired tissue glucose uptake
40. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes
41. Glucose toxicity
42. Pathogenesis of type 2 diabetes: Metabolic and molecular implications of identifying diabetes genes
43. How distinct are the insulin and insulin-like growth factor-I signalling systems?
44. IRS-1 is a common element in insulin and insulin-like growth factor-1 signaling to the phosphatidylinositol 3-kinase
45. Molecular and cellular aspects of the insulin-like growth factor I receptor
46. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatome, and normal, regenerating, and fetal rat liver
47. IGF-I stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM
48. Functional characterization of hybrid receptors composed of a truncated insulin receptor and wild type insulin-like growth factor 1 or insulin receptor
49. Increased expresion of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects
50. Expresion of insulin/IGF-1 hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia
51. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
52. Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans
53. Short-term metabolic effects of recombinant human insulin-like growth factors I in healthy adults
54. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans
55. Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I
56. Role of liver in the pathophysiology of NIDDM
57. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults
58. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy
59. Glucose regulates in vivo glucose-6-phosphatase gene expression in the liver of diabetic rats
60. Carbon flux via the pentose phosphate pathway regulates the hepatic expression of the glucose-6-phosphatase and phosphoenolpyruvate carboxykinase genes in conscious rats
61. Treatment with insulin-like growth factor-I alters capillary permeability in skin and retina